Skip to content

Advertisement

Innovative Therapies

Section information

Section Editor : David Segal

Epigenome-wide association studies result in lists of disease-associated epigenetic abnormalities. To exploit such mutations beyond their use as biomarkers, innovative epigenetic therapies (including but not limited to epigenetic editing) are expected to be further developed into the preclinical and clinical testing phase. This section publishes research and reviews on the development of epigenetic rewriting agents for the treatment of diseases, which do not belong to the conventional class of chemical epigenetic enzyme inhibitors.

  1. Content type: Research

    Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDA...

    Authors: Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, Ananda A. Jaguva Vasudevan, Chenyin Wang, Finn K. Hansen, Constanze Wiek, Helmut Hanenberg, Christoph Gertzen, Holger Gohlke, Matthias U. Kassack, Thomas Kurz, Wolfgang A. Schulz and Günter Niegisch

    Citation: Clinical Epigenetics 2018 10:100

    Published on:

  2. Content type: Research

    Lack of vitamin D (VD) has been associated with colorectal cancer (CRC). VD has anti-inflammatory effects and regulates several cellular pathways by means of its receptor, including epigenetic modifications. A...

    Authors: Daniel Castellano-Castillo, Sonsoles Morcillo, Mercedes Clemente-Postigo, Ana Belén Crujeiras, Jose Carlos Fernandez-García, Esperanza Torres, Francisco José Tinahones and Manuel Macias-Gonzalez

    Citation: Clinical Epigenetics 2018 10:60

    Published on:

  3. Content type: Research

    New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable candidates because these regulators are frequently mutated or der...

    Authors: Alexander S. Hölscher, Wolfgang A. Schulz, Maria Pinkerneil, Günter Niegisch and Michèle J. Hoffmann

    Citation: Clinical Epigenetics 2018 10:1

    Published on:

  4. Content type: Research

    Hypericin-mediated photodynamic therapy (HY-PDT) has recently captured increased attention as an alternative minimally invasive anticancer treatment, although cancer cells may acquire resistance. Therefore, co...

    Authors: Andrea Halaburková, Rastislav Jendželovský, Ján Kovaľ, Zdenko Herceg, Peter Fedoročko and Akram Ghantous

    Citation: Clinical Epigenetics 2017 9:62

    Published on: